Navigating Contradictions: Insights from the Latest Earnings Call on NET Revenue, Pricing Dynamics, and Zanzalintinib's Strategy

Strong Financial Performance:
- Exelixis reported total revenues of approximately $568 million for Q2 2025, including $520 million from cabozantinib franchise net product revenues.
- The growth was driven by robust performance of the cabozantinib U.S. business and significant revenue contributions from new indications in neuroendocrine tumors.

Cabozantinib Franchise Expansion:
- Cabozantinib U.S. franchise net product revenues grew 19% year-over-year to $520 million in Q2 2025, compared to $438 million in Q2 2024.
- The increase was primarily due to commercial demand and contributions from the recently approved net indications.

Pipeline Progress and Pivotal Trials:
- Exelixis announced positive top-line results from STELLAR-303, showing a statistically significant improvement in overall survival for zanzalintinib plus atezolizumab in advanced CRC.
- The progress is attributed to the strategic focus on advancing zanzalintinib as the next oncology franchise opportunity.

Commercial Launch Success in Neuroendocrine Tumors:
- CABOMETYX rapidly became the market leader in the oral second-line plus NET segment, contributing approximately 4% of Q2 2025 net product revenue.
- The strong dynamics of the net launch were driven by effective commercial execution and the alignment of Cabo's data with unmet needs in neuroendocrine tumors.